Endoscopic surgery for early-stage nasopharyngeal cancer
Official title: A Prospective Clinical Trial of Endoscopic Nasopharyngectomy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma Patients
Run by Sun Yat-sen University · NCT03353467 · Data updated 2026-11-12
This study tests if a new type of endoscopic surgery, combined with targeted radiation, can help people with early-stage nasopharyngeal cancer have better outcomes and fewer side effects than traditional surgery.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 228 (estimated) |
| Sponsor | Sun Yat-sen University Academic / other |
| Locations | 5 sites (Guangzhou, Guangdong and 4 other locations) |
| Status | Recruiting |
| Started | October 1, 2017 |
| Main results expected | October 1, 2025 |
| Study ends | October 1, 2028 |
| Registry record updated | June 3, 2021 |
| Trial ID | NCT03353467 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 to 70 with biopsy-proven Stage I nasopharyngeal carcinoma who have not received prior treatment.
✕Probably not a fit
Patients with evidence of relapse, distant metastasis, or uncontrolled life-threatening diseases may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the use of endoscopic nasopharyngectomy as a treatment for patients with newly diagnosed Stage I nasopharyngeal carcinoma. The approach aims to improve surgical outcomes by minimizing complications associated with traditional open surgery, leveraging advancements in endoscopic techniques. Patients will receive endoscopic surgery combined with intensity-modulated radiotherapy, which is designed to enhance treatment efficacy while reducing adverse effects. The study focuses on patients who have not received prior treatment and meet specific health criteria.
Why it matters
Potential benefit: If successful, this approach could provide a less invasive treatment option with fewer complications for patients with early-stage nasopharyngeal carcinoma.
How similar studies have gone: While traditional surgery has been used for recurrent cases, this endoscopic approach is relatively novel and has not been extensively tested in primary nasopharyngeal carcinoma.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Previously untreated, biopsy-proven World Health Organization (WHO) types II or III NPC; Stage I disease (American Joint Committee on Cancer 7th edition); Between 18 and 70 years old; Adequate bone marrow, liver and renal function; Satisfactory performance status: a score of 0 or 1 using the Eastern Cooperative Oncology Group System; Patients provided signed informed consent. Exclusion Criteria: * Evidence of relapse or distant metastasis; History of prior malignancy or previous treatment for NPC; The presence of uncontrolled life-threatening diseases; The investigator considered the patient unable to complete the study.
Where it's running
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China Recruiting -
The First Affiliated Hospital, Sun Yat-Sen University
Guangzhou, Guangdong, China Recruiting -
The First People's Hospital of Foshan
Guangzhou, Guangdong, China Recruiting -
Zhongshan People's Hospital
Zhongshan, Guangdong, China Recruiting -
The People's Hospital of Guangxi Zhuang Autonomous Region
Nanning, Guangxi, China Recruiting
Study contacts
- Study coordinator: Ming-Yuan Chen, MD,Ph.D
- Email: chmingy@mail.sysu.edu.cn
- Phone: 86-13903052650
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Docetaxel and SX-682 in head and neck cancers and prostate cancer
This trial tests a new drug SX-682 together with docetaxel in adults whose head and neck cancers or prostate cancer have returned or spread.
-
Becotatug Vedotin for EGFR-positive relapsed, refractory, or metastatic pediatric solid tumors
This trial will test Becotatug Vedotin, an EGFR-targeted antibody-drug conjugate, to see if it is safe and helps children aged 2–18 with EGFR-positive relapsed, refractory, or metastatic solid tumors.
-
Induction and maintenance with MRG003, Tislelizumab, and Capecitabine for locally recurrent nasopharyngeal cancer
This study tests a treatment combo of MRG003 and a PD-1 blocker first, then continues with Capecitabine plus the PD-1 blocker to see if it helps patients with locally recurrent NPC.
-
Lower-dose (40.2 Gy) versus standard-dose (49.2 Gy) radiotherapy to low‑risk areas for chemosensitive Stage II nasopharyngeal cancer
This trial will try a lower radiotherapy dose (40.2 Gy) instead of the standard 49.2 Gy for people with stage II nasopharyngeal cancer who had a strong response to induction chemo and have undetectable EBV DNA.
-
Screening for early nasopharyngeal (nose) cancer
This project tests whether blood and saliva markers can find nasopharyngeal cancer early in adults aged 35 to 60 who are at higher risk because of ethnicity or family history.
-
Proton versus photon radiation for nasopharyngeal cancer
This trial will test whether proton radiation works at least as well as standard photon radiation for adults newly diagnosed with nasopharyngeal cancer that has not spread.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.